ReviewBritish journal of haematology2020
New developments in von Willebrand disease.
Review in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- [Chinese guideline on the diagnosis and management of von Willebrand disease (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Guideline
- Complement-Coagulation Axis and Metabolic Dysregulation Underlie the Transition from Mild to Severe Heat Stroke: A Combined Clinical and Proteomic Study.Shock (Augusta, Ga.) · 2026Article
- Clinical and laboratory diagnosis of von Willebrand disease.Haematologica · 2026Review
- Structure and multiple functions of von Willebrand factor.Haematologica · 2026Review
- Determination of Fibrinogen Ratio Cutoff Limits Using Indirect Reference Interval Methodology.International journal of laboratory hematology · 2025Article
- Article
- Identifying novel biomarkers for ankylosing spondylitis through proteomic profiling of serum-derived extracellular vesicles.Clinical and experimental medicine · 2025Article
- Article
- Clinical, Phenotypic and Genotypic Characteristics of Von Willebrand Disease in Afro-Caribbeans: Results From a Study in Martinique Island, French West Indies.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- A rare case of type 2A von Willebrand disease with compound heterozygous mutation.Annals of hematology · 2025Article
- 5'-UTR G-Quadruplex-Mediated Translation Regulation in Eukaryotes: Current Understanding and Methodological Challenges.International journal of molecular sciences · 2025Review
- Low von Willebrand factor-unraveling an enigma wrapped in a conundrum.Journal of thrombosis and haemostasis : JTH · 2024Review
- Unexpected massive bleeding during the modified LeFort III advancement surgery for Crouzon syndrome: A case report.Clinical case reports · 2024Article
- Bibliometric analysis of the literature on von Willebrand disease: Research status and trends.Acta bio-medica : Atenei Parmensis · 2023Article
- von Willebrand factor links primary hemostasis to innate immunity.Nature communications · 2022Article
- Von Willebrand disease type 2M: Correlation between genotype and phenotype.Journal of thrombosis and haemostasis : JTH · 2022Article
- Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19.Chemico-biological interactions · 2021Review
- Commonly used anti-von Willebrand factor antibody for multimer analysis cross-reacts with fibronectin, which is difficult to distinguish from von Willebrand factor.Research and practice in thrombosis and haemostasis · 2021Article
- Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding.Journal of thrombosis and haemostasis : JTH · 2021Article
- Prophylactic management of patients with von Willebrand disease.Therapeutic advances in hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Von Willebrand disease (VWD) constitutes the most common inherited human bleeding disorder. It is associated with a mucocutaneous bleeding phenotype that can significantly impact upon quality of life. Despite its prevalence and associated morbidity, the diagnosis and subclassification of VWD continue to pose significant clinical challenges. This is in part attributable to the fact that plasma von Willebrand factor (VWF) levels vary over a wide range in the normal population, together with the multiple different physiological functions played by VWF in vivo. Over recent years, substantial progress has been achieved in elucidating the biological roles of VWF. Significant advances have also been made into defining the pathophysiological mechanisms underpinning both quantitative and qualitative VWD. In particular, several new laboratory assays have been developed that enable more precise assessment of specific aspects of VWF activity. In the present review, we discuss these recent developments in the field of VWD diagnosis, and consider how these advances can impact upon clinical diagnostic algorithms for use in routine clinical practice. In addition, we review some important recent advances pertaining to the various treatment options available for managing patients with VWD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.